Subsequent Events	9 Months Ended
Sep. 30, 2011
Subsequent Events	11. Subsequent Events In October of 2011, the Company raised $434,000 through investors’ exercise of warrants to purchase common stock for cash. Including the $142,000 exercise of warrants by investors at the end of September of 2011, the Company raised $576,000 through investors exercising warrants to purchase common stock for cash during the end of September through October 2011 timeframe. A total of 1,920,000 shares were issued to these investors. No cash or stock commissions were owed from these equity sales. In October of 2011, the Company entered into a new project plan agreement with its contract manufacturing supplier for a batch of drug product with expected delivery by year end. The project plan requires the Company to pay the supplier $177,440 for this drug product. See Note 10.

Subsequent Events

9 Months Ended

Sep. 30, 2011

11. Subsequent Events

In October of 2011, the Company raised $434,000 through investors’ exercise of warrants to purchase common stock for cash. Including the $142,000 exercise of warrants by investors at the end of September of 2011, the Company raised $576,000 through investors exercising warrants to purchase common stock for cash during the end of September through October 2011 timeframe. A total of 1,920,000 shares were issued to these investors. No cash or stock commissions were owed from these equity sales.

In October of 2011, the Company entered into a new project plan agreement with its contract manufacturing supplier for a batch of drug product with expected delivery by year end. The project plan requires the Company to pay the supplier $177,440 for this drug product. See Note 10.